Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kim E. Garbison is active.

Publication


Featured researches published by Kim E. Garbison.


Bioorganic & Medicinal Chemistry Letters | 2012

3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity

Matthew Joseph Fisher; Ryan T. Backer; Vanessa N. Barth; Kim E. Garbison; Joseph Michael Gruber; Beverly A. Heinz; Smriti Iyengar; Sean P. Hollinshead; A.E. Kingston; Steven L. Kuklish; Linglin Li; Eric S. Nisenbaum; Steven C. Peters; Lee A. Phebus; Rosa Maria A. Simmons; Ellen van der Aar

The disclosed 3-phenyl-5-isothiazole carboxamides are potent allosteric antagonists of mGluR1 with generally good selectivity relative to the related group 1 receptor mGluR5. Pharmacokinetic properties of a member of this series (1R,2R)-N-(3-(4-methoxyphenyl)-4-methylisothiazol-5-yl)-2-methylcyclopropanecarboxamide (14) are good, showing acceptable plasma and brain exposure after oral dosing. Oral administration of isothiazole 14 gave robust activity in the formalin model of persistent pain which correlated with CNS receptor occupancy.


Archive | 2012

FLIPR™ Assays for GPCR and Ion Channel Targets

Michelle R. Arkin; Patrick R. Connor; Renee Emkey; Kim E. Garbison; Beverly A. Heinz; Todd R. Wiernicki; Paul A. Johnston; Ramani A. Kandasamy; Nancy B. Rankl; Sitta Sittampalam


Archive | 2012

IP-3/IP-1 Assays

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness


Archive | 2015

Phospho-ERK Assays

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness; Jeffrey R. Weidner; G. Sitta Sittampalam


Archive | 2015

Figure 3: [Agonist concentration response curves. ERK1/2 activation with cells expressing endogenous GPCRs.].

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness; Jeffrey R. Weidner; G. Sitta Sittampalam


Archive | 2015

Figure 4: [Detection of GPCR-induced ERK1/2 activation...].

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness; Jeffrey R. Weidner; G. Sitta Sittampalam


Archive | 2015

Figure 1: [ERK1/2 can be activated by...].

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness; Jeffrey R. Weidner; G. Sitta Sittampalam


Archive | 2015

Figure 2: [AlphaScreen SureFire ERK Assay Principle.].

Kim E. Garbison; Beverly A. Heinz; Mary E. Lajiness; Jeffrey R. Weidner; G. Sitta Sittampalam


Archive | 2012

Figure 8A. [Example of max addition with tip wash in agonist/potentiator assay.].

Michelle R. Arkin; Patrick R. Connor; Renee Emkey; Kim E. Garbison; Beverly A. Heinz; Todd R. Wiernicki; Paul A. Johnston; Ramani A. Kandasamy; Nancy B. Rankl; Sitta Sittampalam


Archive | 2012

Figure 8B. [Carry-over from tips in (a) in subsequent plate (buffer addition only).].

Michelle R. Arkin; Patrick R. Connor; Renee Emkey; Kim E. Garbison; Beverly A. Heinz; Todd R. Wiernicki; Paul A. Johnston; Ramani A. Kandasamy; Nancy B. Rankl; Sitta Sittampalam

Collaboration


Dive into the Kim E. Garbison's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge